

THORATEC CORP  
Form DEFA14A  
August 03, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**SCHEDULE 14A INFORMATION**  
**Proxy Statement Pursuant to Section 14(a) of the**  
**Securities Exchange Act of 1934**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to § 240.14a-12

**THORATEC CORPORATION**

**(Name of registrant as specified in its charter)**

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)**

Payment of Filing Fee (Check the appropriate box):

- x No fee required.
- .. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  - (1) Title of each class of securities to which transaction applies:
  
  - (2) Aggregate number of securities to which transaction applies:
  
  - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
  
  - (4) Proposed maximum aggregate value of transaction:
  
  - (5) Total fee paid:
- .. Fee paid previously with preliminary materials.
- .. Check box if any part of the fee is offset as provided by Exchange Act Rule 240.0-11 and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  - (1) Amount Previously Paid:
  
  - (2) Form, Schedule or Registration Statement No.:
  
  - (3) Filing Party:

(4) Date Filed:

Filed by Thoratec Corporation

Pursuant to Rule 14a-12 under the Securities Exchange Act of 1934

Subject Company: Thoratec Corporation

Commission File No.: 000-49798

## Acquisition FAQs

August 3, 2015

**Employees** we have received many questions related to benefits including medical carriers, the treatment of PTO and reserve disability hours, as well as how severance will be paid out. Until we are through the go-shop period, we are unable to answer these specific questions. As soon as details are available, we will communicate with you.

Thank you for your patience.

### *Compensation*

**1. Please clarify what will be paid on MBOs, both personal and company financial, as well as when the bonus will be paid out.**

When the transaction closes, your 2015 bonus will be paid based on the full year's target amount assuming 100% achievement of personal goals. Our corporate performance will be determined based on the Company's performance up to the close date and calculated based on a full year of performance.

**2. Is the hourly TIP bonus included when discussing MBOs ?**

Yes

**3. Does the 90-day retention period start when the transaction closes?**

Yes

**4. Can you please clarify what is meant by cash compensation? Does it include base only or base plus bonus?**

Cash compensation with regards to severance is base salary. Total Cash Compensation includes base, bonus or incentive.

### *Severance*

**5. Will the enhanced benefits/packages vary between employees that are paid hourly vs. salary?**

Details will be communicated within the next week.

### *Equity*

**6. Will there be taxes taken out of my vested stock sale?**

Standard taxation occurs. Please reference the E\*TRADE website for additional clarification.

## **Important Information**

### ***Additional Information and Where to Find It***

Thoratec Corporation. ( Thoratec or the Company ) intends to file with the Securities and Exchange Commission (the SEC ) a proxy statement in connection with its proposed acquisition by St. Jude Medical, Inc., a Minnesota Corporation and furnish or file other materials with the SEC in connection with the proposed transaction. The definitive proxy statement will be sent or given to the shareholders of the Company and will contain important information about the proposed transaction and related matters. BEFORE MAKING ANY VOTING DECISION, THORATEC S SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND THOSE OTHER MATERIALS CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. The proxy statement and other relevant materials (when they become available), and any other documents filed by Thoratec with the SEC, may be obtained free of charge at the SEC s website at [www.sec.gov](http://www.sec.gov). In addition, security holders will be able to obtain free copies of the proxy statement from Thoratec by contacting Thoratec s Investor Relations by telephone at (925) 847-8600, or by mail Thoratec Corporation, 6035 Stoneridge Drive, Pleasanton, California 94588, Attention: Investor Relations, or by going to Thoratec s Investor Relations page on its corporate website at [www.thoratec.com](http://www.thoratec.com).

### ***Participants in the Solicitation***

Thoratec and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of Thoratec in connection with the proposed transaction. Information regarding the interests of these directors and executive officers in the transaction described herein will be included in the proxy statement described above. Additional information regarding the directors and executive officers of Thoratec is included in proxy statement for its 2015 Annual Meeting, which was filed with the SEC on March 24, 2015, and is supplemented by other public filings made, and to be made, with the SEC by Thoratec.

### ***Forward-Looking Statements***

This document contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those indicated in such forward-looking statements, including, but not limited to, the ability of the parties to consummate the proposed transaction; satisfaction of closing conditions to the consummation of the proposed transaction; the impact of the announcement of the proposed transaction on Thoratec s relationships with its employees, existing customers or potential future customers; and such other risks and uncertainties pertaining to the Thoratec s business as detailed in its filings with the SEC on Forms 10-K and 10-Q, which are available on the SEC s website at [www.sec.gov](http://www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date thereof. Thoratec assumes no obligation to update any forward-looking statement contained in this document.